The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott Stanslaski said.

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized neuromodulation that responds to the patient’s changing needs.